ArticleClinical medicine insights. Circulatory, respiratory and pulmonary medicine2013
Pharmacotherapies for COPD.
Article in Clinical medicine insights. Circulatory, respiratory and pulmonary medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Interventions to improve adherence to pharmacological therapy for chronic obstructive pulmonary disease (COPD).The Cochrane database of systematic reviews · 2021Pooled it
- Dyspnea in Chronic Obstructive Pulmonary Disease: Expert Assessment of Management in Clinical Practice.Pulmonary therapy · 2025Article
- Bronchodilator reversibility testing in morbidly obese non-smokers: a comparative study- few concerns.BMC pulmonary medicine · 2024Article
- Assessment of bronchodilator responsiveness to salbutamol or ipratropium using different criteria in treatment-naïve patients with asthma and COPD.European clinical respiratory journal · 2024Article
- The Functional and Psychosocial Consequences of COPD.Respiratory care · 2023Article
- One class classification for the detection of β2 adrenergic receptor agonists using single-ligand dynamic interaction data.Journal of cheminformatics · 2022Article
- Small airway function measured using forced expiratory flow between 25% and 75% of vital capacity and its relationship to airflow limitation in symptomatic ever-smokers: a cross-sectional study.BMJ open respiratory research · 2022Article
- Evaluation of In-Hospital Management of Inhaler Therapy for Chronic Obstructive Pulmonary Disease.The Canadian journal of hospital pharmacy · 2021Article
- Compatible Stability and Aerosol Characteristics of AtroventPharmaceutics · 2020Article
- When to Use Initial Triple Therapy in COPD: Adding a LAMA to ICS/LABA by Clinically Important Deterioration Assessment.International journal of chronic obstructive pulmonary disease · 2020Article
- Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease.Journal of experimental pharmacology · 2020Review
- Treatment Patterns of New Users of Fluticasone Furoate/Vilanterol in Asthma and COPD in UK Primary Care: Retrospective Cohort Study.Pulmonary therapy · 2019Article
- Inhaled therapies in patients with moderate COPD in clinical practice: current thinking.International journal of chronic obstructive pulmonary disease · 2018Review
- Long-acting bronchodilators with or without inhaled corticosteroids and 30-day readmission in patients hospitalized for COPD.International journal of chronic obstructive pulmonary disease · 2017Article
- Food-Derived Bioactives Can Protect the Anti-Inflammatory Activity of Cortisol with Antioxidant-Dependent and -Independent Mechanisms.International journal of molecular sciences · 2016Article
- Anxiety and depression-Important psychological comorbidities of COPD.Journal of thoracic disease · 2014Review
- Review
- Mitochondria in lung diseases.Expert review of respiratory medicine · 2013Review
- PARC/CCL18 is Associated with Inflammation, Emphysema Severity and Application of Inhaled Corticosteroids in Hospitalized COPD Patients.International journal of chronic obstructive pulmonary diseaseArticle
- Long-acting muscarinic antagonist and long-acting βTherapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review article summarizes the main treatments for chronic obstructive pulmonary disease, their mechanisms, and the key evidence from trials supporting their use. Drug classes covered were short acting beta agonists (SABA), short acting muscarinic antagonists (SAMA), long acting beta agonists (LABA), long acting antimuscarinics (LAMA), inhaled corticosteroids (ICS), LABA/ICS combinations, specific phosphodiesterase (PDE4) inhibitors, non-specific PDE inhibitors, mucolytics, and oxygen. Non-specific therapies, such as opiates for relief of dyspnoea and therapies for smoking cessation, are also covered briefly. For each class of drug, mechanisms of action are described, key clinical trial results are reported, and available agents compared. Finally, the place of each drug in therapy is compared between current worldwide guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.